Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17444679 | 0.89 | L3MBTL1 (0.82) | ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL17444665 | 0.85 | KMT2A (0.57) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL17444657 | 0.80 | KCNJ1 (0.76) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL9321252 | 0.80 | THRB (0.67) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL17444701 | 0.80 | KCNH2 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL14577877 | 0.79 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL17444554 | 0.79 | KCNH2 (0.56) | ALDH1A1SMN1; SMN2MEN1KMT2AHTT | |
| Hydrochloric Acid SCHEMBL5409035 | 0.78 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL5774489 | 0.78 | TSHR (0.57) | ALDH1A1KMT2APOLBHTTMAPT | |
| SCHEMBL17444555 | 0.78 | MEN1 (0.58) | ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| EP-3169683-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen Ltd. (AU) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016008011-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | ALDH1A1 1176/4885SMN1; SMN2 866/4885L3MBTL1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.